(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 3.49% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Collegium Pharmaceutical's revenue in 2025 is $664,283,000.On average, 4 Wall Street analysts forecast COLL's revenue for 2025 to be $23,934,361,851, with the lowest COLL revenue forecast at $23,848,863,620, and the highest COLL revenue forecast at $24,080,930,246. On average, 4 Wall Street analysts forecast COLL's revenue for 2026 to be $24,804,450,988, with the lowest COLL revenue forecast at $24,019,860,082, and the highest COLL revenue forecast at $25,739,467,354.
In 2027, COLL is forecast to generate $23,126,499,997 in revenue, with the lowest revenue forecast at $18,915,679,992 and the highest revenue forecast at $26,674,805,141.